Anti-inflammatory effects of a topical preparation containing nicotinamide, retinol, and 7-dehydrocholesterol in patients with acne: A gene expression study

Clinical, Cosmetic and Investigational Dermatology

Volumn 5, Issue , 2012, Pages 33-37

  Emanuele, Enzo ^a   Bertona, Marco ^a   Altabas, Karmela ^b   Altabas, Velimir ^b   Alessandrini, Giuseppe ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c Dermatology Clinics   (Italy)

Author keywords

Acne; Gene expression; Inflammation; Matrix metalloproteinases; Topical treatment

Indexed keywords

7 DEHYDROCHOLESTEROL; GELATINASE A; GELATINASE B; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MACROPHAGE MIGRATION INHIBITION FACTOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE; RETINOL; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1;

ACNE VULGARIS; ADULT; ADVERSE OUTCOME; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTERLEUKIN 6 GENE; MACROPHAGE MIGRATION INHIBITION FACTOR GENE; MALE; MATRIX METALLOPROTEINASE 1 GENE; MATRIX METALLOPROTEINASE 14 GENE; MATRIX METALLOPROTEINASE 2 GENE; MATRIX METALLOPROTEINASE 9 GENE; MATRIX METALLOPROTEINASE GENE; MONOCYTE CHEMOTACTIC PROTEIN 1 GENE; PILOT STUDY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; TISSUE INHIBITOR OF METALLOPROTEINASE GENE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 84862593840     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: 10.2147/CCID.S29537     Document Type: Article

References (32)

1. Ingram JR, Grindlay DJ, Williams HC. Management of acne vulgaris: an evidence-based update. Clin Exp Dermatol. 2010;35:351-354.
2. Wang KC, Zane LT. Recent advances in acne vulgaris research: insights and clinical implications. Adv Dermatol. 2008;24:197-209.
3. Taylor M, Gonzalez M, Porter R. Pathways to inflammation: acne pathophysiology. Eur J Dermatol. 2011;21:323-333.
4. Collier C, Harper JC, Cafardi JA, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58:56-59.
5. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012;379:361-372.
6. Harper JC, Thiboutot DM. Pathogenesis of acne: recent research advances. Adv Dermatol. 2003;19:1-10.
7. Ayer J, Burrows N. Acne: more than skin deep. Postgrad Med J. 2006;82:500-506.
8. Dessinioti C, Katsambas AD. The role of Propionibacterium acnes in acne pathogenesis: facts and controversies. Clin Dermatol. 2010;28:2-7.
9. Perry AL, Lambert PA. Propionibacterium acnes. Lett Appl Microbiol. 2006;42:185-188.
10. Philips N, Auler S, Hugo R, et al. Beneficial regulation of matrix metalloproteinases for skin health. Enzyme Res. 2011;2011:427285.
11. Kang S, Cho S, Chung JH, et al. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factorkappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166:1691-1699.
12. Papakonstantinou E, Aletras AJ, Glass E, et al. Matrix metalloproteinases of epithelial origin in facial sebum of patients with acne and their regulation by isotretinoin. J Invest Dermatol. 2005;125:673-684.
13. Trivedi NR, Gilliland KL, Zhao W, et al. Gene array expression profiling in acne lesions reveals marked upregulation of genes involved in inflammation and matrix remodeling. J Invest Dermatol. 2006;126: 1071-1079.
14. Choi JY, Piao MS, Lee JB, et al. Propionibacterium acnes stimulates pro-matrix metalloproteinase-2 expression through tumor necrosis factor-alpha in human dermal fibroblasts. J Invest Dermatol. 2008;128:846-854.
15. Kraft J, Freiman A. Management of acne. CMAJ. 2011;183:E430-E435.
16. Tanghetti EA. Combination therapy is the standard of care. Cutis. 2005;76:8-14.
17. Grange PA, Raingeaud J, Calvez V, Dupin N. Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kappaB and MAPK pathways. J Dermatol Sci. 2009;56:106-112.
18. Ruamrak C, Lourith N, Natakankitkul S. Comparison of clinical efficacies of sodium ascorbyl phosphate, retinol and their combination in acne treatment. Int J Cosmet Sci. 2009;31:41-46.
19. Glossmann HH. Origin of 7-dehydrocholesterol (provitamin D) in the skin. J Invest Dermatol. 2010;130:2139-2141.
20. Iraji F, Banan L. The efficacy of nicotinamide gel 4% as an adjuvant therapy in the treatment of cutaneous erosions of pemphigus vulgaris. Dermatol Ther. 2010;23:308-311.
21. Ho ET, Trookman NS, Sperber BR, et al. A randomized, doubleblind, controlled comparative trial of the anti-aging properties of nonprescription tri-retinol 1.1% vs prescription tretinoin 0.025%. J Drugs Dermatol. 2012;11:64-69.
22. Seifert M, Tilgen W, Reichrath J. Expression of 25-hydroxyvitamin D-1alpha-hydroxylase (1alphaOHase, CYP27B1) splice variants in HaCaT keratinocytes and other skin cells: modulation by culture conditions and UV-B treatment in vitro. Anticancer Res. 2009;29:3659-3667.
23. Konishi N, Endo H, Oiso N, Kawara S, Kawada A. Acne phototherapy with a 1450-nm diode laser: an open study. Ther Clin Risk Manag. 2007;3:205-209.
24. Namazi MR. Nicotinamide in dermatology: a capsule summary. Int J Dermatol. 2007;46:1229-1231.
25. Amann PM, Schadendorf D, Owen RW, et al. Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaT. Exp Dermatol. 2011;20:373-375.
26. Nieves NJ, Ahrens JM, Plum LA, et al. Identification of a unique subset of 2-methylene-19-nor analogs of vitamin D with comedolytic activity in the rhino mouse. J Invest Dermatol. 2010;130:2359-2367.
27. Kim J. Review of the innate immune response in acne vulgaris: activation of Toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology. 2005;211:193-198.
28. Fabbrocini G, Annunziata MC, D'Arco V, et al. Acne scars: pathogenesis, classification and treatment. Dermatol Res Pract. 2010;2010:893080.
29. Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro-and antiinflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878-888.
30. Pajulo OT, Pulkki KJ, Alanen MS, et al. Correlation between interleukin-6 and matrix metalloproteinase-9 in early wound healing in children. Wound Repair Regen. 1999;7:453-457.
31. Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29: 313-326.
32. Grieb G, Merk M, Bernhagen J, et al. Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect. 2010;23:257-264.